App-Quantinova.ai

Evaluation of Quality of Biomarker Data Capture by Peripheral Sites in an International, Cooperative Study: Analysis of 104 Cases From the T-Cell Project.

A. Seragnoli - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral T-cell lymphoma

N/A

Mutations of STAT6 DNA Binding Domain Are Characteristic of PMBL and Belong to the Genetic Signature of This Entity.

Francois Lemonnier - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

Genetic Abnormalities in Follicular Lymphoma and Transformed Follicular Lymphoma.

Timothy McKeithan - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402).

Fangxin Hong - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Alpha-thalassemia myelodysplasia syndrome

Ibritumomab tiuxetan with yttrium-90

AML Cells Have Altered Mitochondrial Biogenesis and Low Spare Reserve Capacity in Their Respiratory Chain That Renders Them Susceptible to Oxidative Metabolic Stress.

Timothy E Chung - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

Palmitic acid

Whole Exome Sequencing Analysis in AML with Normal Karyotype Not Harboring FLT3/ITD Mutation Reveals Novel Genetic Alterations.

Namshin Kim - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

N/A

Glutaminase Inhibition Selectively Slows the Growth of Primary Acute Myeloid Leukemia (AML) Cells with Isocitrate Dehydrogenase (IDH) Mutations.

Sung Ah Jun - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Myeloid neoplasms

Glutamine

The Valproic Acid-Fludarabine Combination Induces a Synergistic Response in Chronic Lymphocytic Leukemia Via a Mechanism Involving the Lysosomal Protease Cathepsin B.

David Szwajcer - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Vorinostat

An Open-Label Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in the Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL).

Harminder Paul - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Chronic Lymphocytic Leukemia

Dexamethasone

Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib.

H. Jean Khoury - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Interferon

Tifab, a Novel Candidate Gene in Deletion Chromosome 5q, Contributes to Deregulation of NF-?B Signaling in MDS/AML.

Andres Jerez - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Myelodysplastic Syndrome

N/A

BCR/ABL Transcript At 3 Months Predicts Long-Term Outcomes Following Second Generation Tyrosine Kinase Inhibitor Therapy in the Patients with CML in Chronic Phase Who Failed Imatinib.

Hong Gi Lee - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

dasatinib

The RNA Editase ADAR1 Promotes Malignant Progenitor Reprogramming in Chronic Myeloid Leukemia.

Leslie Crews-Robertson - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Interferon

Three-Dimensional Nuclear Telomeric Organization (3D) of Chronic Myeloid Leukemia Patients Predicts Accelerated Phase and Blast Crisis.

Ferdinando de Paula Silva - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

N/A

Long-Term Follow-up of Ongoing Patients in 2 Studies of Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.

Jeffrey H. Lipton - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Chronic Myelogenous Leukemia

Omacetaxine mepesuccinate

Longterm Serial Transplantability of BCR-ABL+ Chronic Phase CML Cells Is Predicted by a 6-Week LTC-IC Assay.

Philip A Beer - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Cardiofaciocutaneous syndrome

L-Tyrosine

Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.

Ranjana H. Advani - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral neuropathy

monomethyl auristatin E

High Risk of Error in Categorizing Treatment Response in Individual CML Patients by Standard Cytogenetic Analysis or PCR Assay with High CV: A Bayesian Analysis

Pierre Laneuville - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

N/A

Nilotinib

Chronic Myeloid Leukemia Patients Undergoing Interferon Alpha Therapy Exhibit Normal Peripheral Blood Gamma Delta T Cells That May Be Expanded in Vitro to Generate Predominantly CD45RA-Positive Effector Memory Cells for Immunotherapy

Anna Kreutzman - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Interferon alpha

SF3B1 Mutations Are Associated with Favorable Cytogenetics in Patients with Myelodysplastic Syndromes with Ring Sideroblasts

David Faucher - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Myelodysplastic Syndrome

N/A

Filters

28841 Abstracts